Antituberculosis treatment halves risk of uveitis recurrence
In patients with latent tuberculosis (TB)-associated uveitis, treatment with an anti-TB drug cuts the risk of uveitis recurrence by half and delays the onset of first recurrence, as reported in a recent study.
Researchers looked at 199 eyes of 129 patients, of whom 89 patients (69 percent) received anti-TB treatment. Uveitis was managed using local and systemic anti-inflammatory and immunosuppressive therapy.
Data on clinical outcome, vision and treatment were gathered and analysed. Outcomes of interest included best corrected visual acuity (BCVA) and rate of disease recurrence.
Over the follow-up period, mean change in BCVA following treatment was 4.5±1.4 letters. No significant difference was observed between eyes of patients receiving anti-TB treatment and those who did not.
Uveitis recurrence occurred in 68 eyes (34.9 percent; 0.64±0.08 recurrences per year), with eyes of patients receiving anti-TB treatment less likely to develop a recurrence (29.5 percent vs 48.2 percent).
Specifically, anti-TB treatment reduced the odds of developing recurrence by more than half (odds ratio, 0.47; 95 percent CI, 0.29–0.77; p=0.003). Eyes of patients who received the treatment recurred at an estimated median of 120 months vs 51 months in eyes of those who were not treated with an anti-TB drug (p=0.005).
The present data provide positive evidence of the benefit of treating latent TB-related uveitis with an anti-TB drug in addition to appropriate local and systemic anti-inflammatory therapy, researchers said.